Syncona Limited Result of AGM (4383H)

TIDMSYNC

RNS Number : 4383H

Syncona Limited

03 August 2021

Syncona Limited

Result of Annual General Meeting and Retirement of Director

3 August 2021

At the Annual General Meeting of the Syncona Limited (the "Company") held today, all Resolutions as set out in the 'Notice of the 2021 Annual General Meeting' dated 1 July 2021 sent to shareholders of the Company (the "Notice") were duly passed.

Resolutions 1 to 13 were proposed as Ordinary Resolutions. Resolution 14 was proposed as a Special Resolution and Resolution 15 was proposed as an Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the Notice, are noted below:

 
 No   Resolution                      For       Discretion      Against        Abstain 
                                                                              (withheld) 
      Receive and consider 
       the Annual Audited 
       Financial Statements 
       of the Company for 
       the year ended 31 
       March 2021, together 
       with the Reports 
       of the Directors 
 1     and Auditors thereon       485,406,865       0           189,929         2,418 
                                    (9.96%)        (0%)         (0.04%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Re-appointment of 
       Deloitte LLP (Guernsey 
 2     Branch) as Auditors        485,338,006       0           68,688         192,518 
                                    (99.99%)       (0%)         (0.01%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Authorise the Directors 
       to determine the 
       remuneration of the 
 3     Auditors                   485,591,907       0            7,305            0 
                                    (99.99%)       (0%)         (0.01%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Re-elect Melanie            463,380,320 
 4     Gee as a Director            (96.42%)        0         17,192,066      5,026,826 
                                                   (0%)         (3.58%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Elect Virginia Holmes       485,588,541 
 5     as a Director                (99.99%)        0        4,756 (0.01%)      5,915 
                                                   (0%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Re-elect Rob Hutchinson     485,552,870 
 6     as a Director                (99.99%)        0           39,924          6,418 
                                                   (0%)         (0.01%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Re-elect Nigel Keen         485,550,870 
 7     as a Director                (99.99%)        0           41,924          6,418 
                                                   (0%)         (0.01%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Re-elect Kemal Malik 
 8     as a Director              485,552,123       0           38,756          8,333 
                                    (99.99%)       (0%)         (0.01%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Re-elect Nicholas 
 9     Moss as a Director         485,550,870       0           41,924          6,418 
                                    (99.99%)       (0%)         (0.01%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Re-elect Gian Piero 
 10    Reverberi as a Director    485,554,038       0           38,756          6,418 
                                    (99.99%)       (0%)         (0.01%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Approve the report 
       on implementation 
       of the Remuneration 
       Policy for Non-Executive   483,970,337                  1,618,992 
 11    Directors                    (99.67%)        0           (0.33%)         9,883 
                                                   (0%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Authority to allot                                       1,464,359 
 12    and issue shares           484,125,810       0            (0.3%)         9,043 
                                    (99.7%)        (0%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Increase the maximum 
       aggregate amount 
       of fees for all the 
       Board collectively 
       in any financial 
       year from GBP500,000 
 13    to GBP1,000,000            468,468,131       0         16,378,940       752,141 
                                    (96.62%)       (0%)         (3.38%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Authorise the Company 
       to purchase its own 
 14    shares                     485,356,393     11,377        226,656         4,786 
                                    (99.94%)      (0.01%)       (0.05%) 
     --------------------------  ------------  -----------  --------------  ------------ 
      Disapply pre-emption        485,561,682     11,377 
 15    rights                       (99.98%)      (0.01%)       19,631          6,522 
                                                                (0.01%) 
     --------------------------  ------------  -----------  --------------  ------------ 
 

A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

In addition, the Company confirms that, in line with the announcement made previously, Tom Henderson has retired from the Board of the Company with effect from the close of the AGM.

Melanie Gee, Chair of Syncona, commented:

"On behalf of the Board and all our stakeholders, I would like to thank Tom for his significant contribution to both Syncona and the Syncona Foundation over the last nine years. Tom was instrumental in the creation of The Battle Against Cancer Investment Trust (BACIT) in 2012, an innovative investment company that persuaded underlying fund managers to provide their services without charging a fee, and alongside that donated a percentage of its net asset value each year to charity. Tom also played an important role in BACIT's merger with Syncona Partners in 2016, thereby forming the Syncona of today.

Tom remains the Chair of the Foundation, to which Syncona continues to make significant donations, and we look forward to continuing to benefit from his expertise and passion to support the charities to which the Foundation donates and the individuals and families that they support."

In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

The full text of the resolutions can be found in the Notice, which is available on the Company's website at https://www.synconaltd.com/investors/shareholder-information/shareholder-documents/ .

Enquiries

Syncona Limited

Annabel Clay/Fergus Witt

Tel: [phone]

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: [phone]

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com.

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding, building and funding a portfolio of global leaders in life science, to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUPUGWRUPGGGW

(END) Dow Jones Newswires

August 03, 2021 07:32 ET (11:32 GMT)